氟苯达唑作为一种杀微丝蚴药物：历史与背景。
Flubendazole as a macrofilaricide: History and background.
机构信息
Institute of Parasitology, McGill University, Ste-Anne-de-Bellevue, Québec, Canada.
NTDSC/MDP, Task Force for Global Health, Decatur, Georgia, United States of America.
出版信息
PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0006436. doi: 10.1371/journal.pntd.0006436. eCollection 2019 Jan.
Abstract
Benzimidazole anthelmintics have long been employed for the control of soil-transmitted helminth infections. Flubendazole (FBZ) was approved in 1980 for the treatment of gastrointestinal nematode infections in both veterinary and human medicine. It has also long been known that parenteral administration of FBZ can lead to high macrofilaricidal efficacy in a variety of preclinical models and in humans. As part of an effort to stimulate the discovery and development of new macrofilaricides, particularly for onchocerciasis, research has recently been devoted to the development of new formulations that would afford high oral bioavailability of FBZ, paving the way for potential clinical development of this repurposed drug for the treatment of human filariases. This review summarizes the background information that led to this program and summarizes some of the lessons learned from it.
摘要
苯并咪唑类驱虫药长期以来一直被用于控制土壤传播性蠕虫感染。氟苯达唑（FBZ）于 1980 年被批准用于兽医和人类医学中治疗胃肠道线虫感染。长期以来，人们还知道，静脉内给予 FBZ 可导致多种临床前模型和人类中出现高的大丝虫杀灭效果。作为努力刺激新的大丝虫杀剂的发现和开发的一部分，特别是用于盘尾丝虫病，最近的研究致力于开发新的制剂，以提供 FBZ 的高口服生物利用度，为重新利用这种药物治疗人类丝虫病的潜在临床开发铺平道路。本综述总结了导致该计划的背景信息，并总结了从中获得的一些经验教训。
相似文献
1
Flubendazole as a macrofilaricide: History and background.
PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0006436. doi: 10.1371/journal.pntd.0006436. eCollection 2019 Jan.
2
Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs.
Expert Rev Anti Infect Ther. 2011 May;9(5):497-501. doi: 10.1586/eri.11.30.
3
Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
PLoS Negl Trop Dis. 2015 Feb 20;9(2):e0003534. doi: 10.1371/journal.pntd.0003534. eCollection 2015 Feb.
4
Progress and challenges in the discovery of macrofilaricidal drugs.
Expert Rev Anti Infect Ther. 2011 Aug;9(8):681-95. doi: 10.1586/eri.11.76.
5
The role of albendazole in programmes to eliminate lymphatic filariasis.
Parasitol Today. 1999 Sep;15(9):382-6. doi: 10.1016/s0169-4758(99)01486-6.
6
Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Parasit Vectors. 2018 Jan 31;11(1):70. doi: 10.1186/s13071-018-2655-5.
7
Research notes from the Onchocerciasis Chemotherapy Research Centre, Ghana.
Ann Trop Med Parasitol. 1997 Oct;91(7):703-11. doi: 10.1080/00034989760437.
8
A murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasis.
Parasit Vectors. 2014 Oct 24;7:472. doi: 10.1186/s13071-014-0472-z.
9
Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.
Acta Trop. 2011 Sep;120 Suppl 1:S33-8. doi: 10.1016/j.actatropica.2010.09.009. Epub 2010 Oct 8.
10
Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
Trop Med Int Health. 2006 May;11(5):718-28. doi: 10.1111/j.1365-3156.2006.01606.x.
引用本文的文献
1
Current perspectives in the epidemiology and control of lymphatic filariasis.
Clin Microbiol Rev. 2025 Jun 12;38(2):e0012623. doi: 10.1128/cmr.00126-23. Epub 2025 Apr 2.
2
A review of feature selection strategies utilizing graph data structures and Knowledge Graphs.
Brief Bioinform. 2024 Sep 23;25(6). doi: 10.1093/bib/bbae521.
3
The efficacy of the benzimidazoles oxfendazole and flubendazole against is dependent on the adaptive and innate immune system.
Front Microbiol. 2023 Jun 27;14:1213143. doi: 10.3389/fmicb.2023.1213143. eCollection 2023.
4
Survival of worm masses of Onchocerca ochengi in gerbils and hamsters: implications for the development of an in vivo macrofilaricide screening model.
Parasitol Res. 2023 Jul;122(7):1581-1591. doi: 10.1007/s00436-023-07859-7. Epub 2023 May 8.
5
Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma.
Int J Biol Sci. 2023 Apr 23;19(7):2270-2288. doi: 10.7150/ijbs.81415. eCollection 2023.
6
A PI3Kγ signal regulates macrophage recruitment to injured tissue for regenerative cell survival.
Dev Growth Differ. 2022 Oct;64(8):433-445. doi: 10.1111/dgd.12809. Epub 2022 Sep 21.
7
Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.
Int J Mol Sci. 2022 Apr 11;23(8):4220. doi: 10.3390/ijms23084220.
8
Investigating Flubendazole as an Anthelmintic Treatment for Guinea Worm (Dracunculus medinensis): Clinical Trials in Laboratory-Reared Ferrets and Domestic Dogs in Chad.
Am J Trop Med Hyg. 2022 Feb 28;106(5):1456-65. doi: 10.4269/ajtmh.21-1222.
9
Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers.
Int J Mol Sci. 2022 Jan 4;23(1):519. doi: 10.3390/ijms23010519.
10
Adoptive Transfer of Immune Cells Into RAG2IL-2Rγ-Deficient Mice During Infection: A Novel Approach to Investigate Filarial-Specific Immune Responses.
Front Immunol. 2021 Nov 18;12:777860. doi: 10.3389/fimmu.2021.777860. eCollection 2021.
本文引用的文献
1
Macrofilaricidal efficacy of single and repeated oral and subcutaneous doses of flubendazole in Litomosoides sigmodontis infected jirds.
PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0006320. doi: 10.1371/journal.pntd.0006320. eCollection 2019 Jan.
2
Efficacy of subcutaneous doses and a new oral amorphous solid dispersion formulation of flubendazole on male jirds (Meriones unguiculatus) infected with the filarial nematode Brugia pahangi.
PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0006787. doi: 10.1371/journal.pntd.0006787. eCollection 2019 Jan.
3
Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.
PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0007026. doi: 10.1371/journal.pntd.0007026. eCollection 2019 Jan.
4
Potential Role for Flubendazole in Limiting Filariasis Transmission: Observations of Microfilarial Sensitivity.
Am J Trop Med Hyg. 2018 Jan;98(1):21-26. doi: 10.4269/ajtmh.17-0390.
5
Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis.
Sci Rep. 2017 Mar 16;7(1):210. doi: 10.1038/s41598-017-00322-5.
6
Species differences in hepatic biotransformation of the anthelmintic drug flubendazole.
J Vet Pharmacol Ther. 2017 Oct;40(5):493-499. doi: 10.1111/jvp.12383. Epub 2017 Jan 16.
7
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005163. doi: 10.1371/journal.pntd.0005163. eCollection 2017 Jan.
8
Profiling the macrofilaricidal effects of flubendazole on adult female Brugia malayi using RNAseq.
Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):288-296. doi: 10.1016/j.ijpddr.2016.09.005. Epub 2016 Oct 1.
9
Research for new drugs for elimination of onchocerciasis in Africa.
Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):272-286. doi: 10.1016/j.ijpddr.2016.04.002. Epub 2016 May 19.
10
The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014).
Infect Dis Poverty. 2016 May 24;5(1):54. doi: 10.1186/s40249-016-0147-4.
Zotero 插件